secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-276000
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports Q3 2025 net loss of $21.1M; highlights 34% ORR with rezatapopt in PYNNACLE study
--------------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities of $129.3M as of Sept 30, 2025; cash runway to end of Q1 2027.
- Overall response rate of 34% (35/103 patients) in Phase 2 PYNNACLE study; 46% ORR in ovarian cancer cohort with median duration of response of 8.0 months.
- Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.
- Net loss for Q3 2025 was $21.1M vs $19.2M in Q3 2024, driven by increased R&D costs of $18.2M.
- R&D expenses increased to $18.2M from $16.9M due to advancement of rezatapopt program; G&A decreased to $4.3M from $4.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/0001193125-25-276000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000119312525276000/pmvp-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-276000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer